Heart rhythm showdown: ablation may beat drugs for ventricular tachycardia
NCT ID NCT05524077
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether a procedure called catheter ablation works better than anti-arrhythmic drugs for people with structural heart disease who have had a dangerous fast heart rhythm (ventricular tachycardia). About 162 participants will be randomly assigned to either ablation or standard drug therapy. The goal is to see which approach better reduces repeat episodes, life-threatening storms of fast rhythms, and death over about 18 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- catheter ablation (a procedure using a thin tube to destroy heart tissue causing abnormal rhythms)
- What this could lead to
- If successful, this could show that catheter ablation is a better first-line treatment than drugs for controlling dangerous heart rhythms and reducing hospital visits.
- What could go wrong
- This is a mid-sized trial (162 people) and results may not apply to all heart disease types. Ablation is invasive and carries risks like bleeding or heart damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 162 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2020
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients will be eligible for inclusion if they have: 1. ≥1 prior episode of sustained VT in the prior 6 months; 1. Spontaneous VT: ≥1 episode of monomorphic VT treated by anti-tachycardia pacing (ATP) and/or internal shock by an ICD; lasting ≥30 seconds in the absence of intra-cardiac device therapy that could either be self-terminating or require reversion by pharmacological therapy or external cardioversion; 2. Spontaneous VT: ≥1 episode of sustained spontaneous monomorphic VT lasting ≥30 seconds documented on Holter, ECG, Loop recorder or other cardiac monitoring device that could either be self-terminating or require reversion by pharmacological therapy or external cardioversion; 3. Inducible VT: with syncope or palpitations - inducible VT defined as sustained monomorphic VT of CL ≥200 ms lasting for ≥10 s during a cardiac electrophysiology study (note with 4 extrastimuli with or without provocation with isoprenaline); 2. Already a recipient of an implanted cardiac device such as a pacemaker, defibrillator or a cardiac resynchronisation therapy device and/or is indicated to receive one given a new diagnosis of structural heart disease, based on current guideline recommendations; 3. Aged ≥18 years. Exclusion Criteria: Patients will be excluded if they are: 1. Unable or unwilling to provide informed consent or patients physician feels there is not significant equipoise to justify randomisation; 2. Women who are pregnant, breast feeding; 3. Medical illness with an anticipated life expectancy \<3 months; 4. Unable to complete study procedures or unwilling to be followed up; 5. Have a concomitant illness, physical impairment or mental condition which in the opinion of the study team/ primary care physician could interfere with the conduct of the study including outcome assessments; 6. Known channelopathy such as long QT, short QT, Brugada syndrome, catecholaminergic polymorphic VT; 7. Known prior diagnosis of no structural heart disease, or idiopathic ventricular arrhythmia.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Arrhythmogenic left ventricular cardiomyopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gold Coast University Hospital
Southport, Queensland, 4215, Australia
-
John Hunter Hospital
New Lambton Heights, New South Wales, 2305, Australia
-
Nepean Hospital
Kingswood, New South Wales, 2747, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Royal North Shore Hospital
Saint Leonards, New South Wales, 2065, Australia
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
The Prince Charles Hospital
Chermside, Queensland, 4032, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new electric pulse technique tame Post-Heart-Attack heart rhythms faster?
- A glowing dye could expose hidden heart scarring
- Can a higher dose of heart radiation stop dangerous rhythms?
- Heart scans may unlock hidden risks in minority communities
- Can two advanced heart maps guide a more precise fix for dangerous arrhythmias?
- Can immune profiling unlock the hidden stages of tuberculosis?